Management of patients with follicular lymphoma treated first line with obinutuzumab

Stephen Opat, Michael Dickinson, Chan Yoon Cheah, Constantine Tam, Joy Boulos, Alison Nicole Thorburn, Judith Trotman

Research output: Contribution to journalArticleResearchpeer-review


Recently, obinutuzumab was included in the Australian Pharmaceutical Benefits Scheme for use in first line, advanced or bulky stage 2, follicular lymphoma, providing more immunochemotherapy treatment options available than ever before. Rituximab with chemotherapy has been the standard of care since reimbursement in the late 1990s; however, obinutuzumab-based regimens have shown superior progression-free survival in comparison to rituximab-based options, albeit at an increased risk of grade ≥3 adverse events. As median overall survival approaches 20 years or more, the long-term effects and sequencing of any strategy should be considered. Here we discuss the considerations for selection of front-line therapy, based on evidence and local Australian clinician experience, in the management of first line follicular lymphoma.

Original languageEnglish
Pages (from-to)3-11
Number of pages9
JournalAsia-Pacific Journal of Clinical Oncology
Issue numberS3
Publication statusPublished - 1 May 2019


  • chemoimmunotherapy
  • follicular lymphoma
  • obinutuzumab
  • rituximab

Cite this